← Eichor
Study identifier: NCT07279935 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.

Condition: Non-small Cell Lung Cancer  ·  Sponsor: AstraZeneca

PhasePhase 4
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is designed as a multi-cohort trial based on various patient biomarkers study with the potential to include new study treatment in the future. EGFR-sensitive mutation-positive patients with distant recurrence after adjuvant osimertinib treatment for EGFRm resectable SIB-IIIA NSCLC and scheduled to receive osimertinib plus chemotherapy will be enrolled in cohort 1. In this cohort, approximately 100 patients will be recruited from 25 sites in China. The enrolment period is planned to be approximately 16 months.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center  ·  1-877-240-9479  ·  information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (33)

Research SiteBeijing, ChinaNot Yet Recruiting
Research SiteBeijing, ChinaRecruiting
Research SiteBeijing, ChinaNot Yet Recruiting
Research SiteChengdu, ChinaRecruiting
Research SiteChengdu, ChinaNot Yet Recruiting
Research SiteChongqing, ChinaNot Yet Recruiting
Research SiteFuzhou, ChinaRecruiting
Research SiteFuzhou, ChinaRecruiting
Research SiteGuangzhou, ChinaNot Yet Recruiting
Research SiteGuangzhou, ChinaWithdrawn
Research SiteGuangzhou, ChinaNot Yet Recruiting
Research SiteHangzhou, ChinaRecruiting

+ 21 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07279935